RECOMMENDATIONS FOR COVID-19 PREVENTION AND TESTING FOR HEMATOPOIETIC CELL TRANSPLANT CENTERS IN BRAZIL

September 2023

Authors

  • Ana Verena de Almeida Mendes Hospital São Rafael, Universidade Baiana, Brazil
  • Fabianne Carlesse Universidade Federal de São Paulo - UNIFESP/EPM, Brazil
  • Jessica Ramos Hospital Sírio Libanês
  • Márcia Garnica Maiolin Universidade Federal do Rio de Janeiro, Complexo Hospitalar de Niterói, Brazil
  • Clarisse Martins Machado Laboratório de Virologia, Instituto de Medicina Tropical da faculdade de Medicina da USP, Brazil

DOI:

https://doi.org/10.46765/2675-374X.2023v4n3p206

Abstract

From February 2020 to May 2023, 37,625,916 cases of COVID-19 were recorded in Brazil, which led to 2,173,359 hospitalizations due to severe acute respiratory syndrome (SARS) with 703,291 deaths due to COVID-19. More than 14 million cases were registered in 2021 and 2022. However, there was a significant drop in the number of hospitalizations for SARS and the COVID-19 fatality rate in 2022, which certainly reflects the impact of mass vaccination in the country, started in February 2021.

Downloads

Published

10/17/2023

How to Cite

Mendes, A. V. de A. ., Carlesse, F. ., Ramos, J., Garnica Maiolin, M. ., & Machado, C. M. (2023). RECOMMENDATIONS FOR COVID-19 PREVENTION AND TESTING FOR HEMATOPOIETIC CELL TRANSPLANT CENTERS IN BRAZIL : September 2023. JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY, 4(3), 206. https://doi.org/10.46765/2675-374X.2023v4n3p206

Issue

Vol. 4 No. 3 (2023): Journal of Bone Marrow Transplantation and Cellular Therapy

Section

Original article

License

Copyright (c) 2023 JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

License and Copyright Policy

The Journal of Bone Marrow Transplantation and Cellular Therapy (JBMTCT) adopts an open access policy, ensuring that all published articles are freely available to the public without restrictions.

  1. License

    • All articles published in JBMTCT are licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0).
    • This license permits anyone to:
      • Share: Copy and redistribute the material in any medium or format.
      • Adapt: Remix, transform, and build upon the material for any purpose, even commercially.
    • The only requirement is that appropriate credit is given to the original authors and source, a link to the license is provided, and any changes made are indicated.

    More information about the license can be found here: Creative Commons Attribution 4.0 International License.

  2. Authors’ Rights

    • Authors retain the copyright to their work.
    • Authors grant JBMTCT the right to publish the work and make it openly accessible online.
    • Authors are free to:
      • Distribute the published version of their article (e.g., post it on personal websites or institutional repositories).
      • Use the article in future works, presentations, or derivative publications, as long as the original publication in JBMTCT is properly acknowledged.

  3. No Embargo

    • There is no embargo period; articles are made freely available immediately upon publication.

  4. Ethical Use

    • Users of JBMTCT articles must ensure proper citation of the authors and the journal.
    • Articles must not be used in ways that violate ethical or legal standards.

  5. Disclaimer

    • While JBMTCT aims to ensure the accuracy and reliability of published content, the journal and its editors are not responsible for the consequences of its use.

For any questions regarding our licensing terms, please contact us at: journalbmtct@sbtmo.org.br 

JBMTCT is committed to the principles of open access to advance knowledge and scientific collaboration.